AI Consensus Investment Thesis
UCB (UCB) Stock Forecast and AI Rating
Forecast targets and rating
Final recommendation
BUY
Calculated from the frozen synthesized path using the same return, horizon, volatility and dividend rules as individual opinions.
1-Year
STRONG BUY€242
+16.5%+17.1% incl. dividends5-Year
BUY€358
+72.0%+76.4% incl. dividendsLatest flagship insight
Biologic Replacement Cycle Overwhelms Patent Cliffs Creating Attractive Valuation Inflection
High consensus confirms that multi-indication immunology volume growth decisively overcomes legacy antiepileptic patent runoff, driving structural operating leverage. The primary risk centers on US gross-to-net rebate compression and capital intensity from recent acquisitions, while cash conversion validates long-term earnings durability.
This is the latest published deep-analysis batch. Audit published forecasts in full transparency
Warren Buffett (Value Purist), Universal Investor (Polymath), Superintelligence (Anthropologist), Elon Musk (Visionary), Ray Dalio (Strategist), J.P. Morgan (Titan), Michael Burry (Vulture), Machiavelli (Insider), Sherlock Holmes (Whistleblower). Some archetypes run in multiple modes, resulting in 14 advisors total.
Gemini
Claude
ChatGPTExecutive Summary
Dotted terms open concise definitions. Browse technical terms
If you invested $10,000 in UCB at the forecast anchor (2026-09-18): $18,350 in five years versus $13,892 for S&P 500 benchmark.
* Return is calculated incl. 0.5% net dividend yield for UCB.
20-quarter synthesized forecastPrice targets, quarterly returns and the reasoning behind each stepView tableClose table
Frozen forecast from 18 Sept 2026. Prices in EUR; returns exclude dividends. Each quarter is compounded from the previous quarter.
Swipe the table horizontally to read every column.
| Quarter | Target (EUR) | Quarter return | Total return | Forecast rationale |
|---|---|---|---|---|
| Q4 2026 | 215.97 | +3.78% | +3.78% | Commercial prescription updates demonstrate accelerating dermatology uptake, offsetting Briviact generic entry. Modest valuation recovery begins from oversold levels, though higher sovereign yields keep broader European equity multiples restrained across defensive sectors. |
| Q1 2027 | 228.36 | +5.74% | +9.74% | Full-year financial disclosures confirm underlying operating margin resilience, disproving fears of severe second-half profitability collapse. Management guidance upgrades and clarifying disclosures regarding recurring cash generation prompt sell-side upward revisions. |
| Q2 2027 | 234.80 | +2.82% | +12.83% | Expanded indications in axial spondyloarthritis drive steady volume gains. However, visible cash absorption from acquired pipeline programs and ongoing biologics facility construction temper equity momentum, producing modest periodic consolidation. |
| Q3 2027 | 242.46 | +3.26% | +16.51% | First-half results reveal strong organic patient expansion offsetting pharmacy benefit manager rebate widening. Working capital distortions normalize, restoring institutional confidence in cash conversion as rare disease revenue lines achieve self-sustaining scale. |
| Q4 2027 | 249.63 | +2.96% | +19.96% | Year-end commercial formulary agreements secure preferred access across major commercial health plans. Easing policy rate volatility lowers equity discount hurdles, supporting steady valuation re-rating into the close of the fiscal year. |
| Q1 2028 | 262.46 | +5.14% | +26.12% | Annual results confirm that flagship immunology revenue growth has permanently outpaced legacy neurology patent runoff. Expanding operating cash flows support an enhanced progressive dividend, attracting conservative institutional capital across continental exchanges. |
| Q2 2028 | 269.39 | +2.64% | +29.45% | Pediatric and adolescent label approvals widen the addressable demographic footprint. Strong volume expansion absorbs European statutory pricing reviews, maintaining steady margin defense and supporting measured periodic share price appreciation. |
| Q3 2028 | 275.56 | +2.29% | +32.42% | Interim reporting highlights resilient unit demand across international markets, partially countered by negotiated Medicare price disclosures on legacy anti-TNF lines. Core biologic execution keeps operating cash flow growth positive. |
| Q4 2028 | 283.80 | +2.99% | +36.38% | Commercial manufacturing scale delivers tangible unit cost efficiencies. Fortress balance sheet strength and visible patent protection extending into the 2030s command a distinct scarcity premium relative to European peers. |
| Q1 2029 | 295.89 | +4.26% | +42.19% | Full-year reporting proves operating leverage fruition as recurring free cash flow crosses substantial milestones. Management initiates opportunistic share repurchases, retiring equity and accelerating per-share intrinsic value compounding. |
| Q2 2029 | 299.44 | +1.20% | +43.89% | Late-stage clinical trial expenditures for acquired cell therapy and autoimmune assets increase slightly, moderating quarterly profit growth. Stable chronic prescription refills preserve baseline operational stability without negative earnings surprises. |
| Q3 2029 | 306.72 | +2.43% | +47.39% | Geographic expansion into secondary Asian and Latin American markets generates diversified top-line contributions. High royalty flow-through from bone-health partnerships reinforces group operating income against regional reimbursement adjustments. |
| Q4 2029 | 313.16 | +2.10% | +50.49% | Phase 2 clinical readouts validate acquired immunology pipeline optionality, extending cash flow visibility. Sustained high cash conversion prompts year-end portfolio reweighting toward defensive, self-funding biopharmaceutical leaders. |
| Q1 2030 | 323.96 | +3.45% | +55.68% | Annual financial figures showcase peak operating leverage, with adjusted operating margins stabilizing in the high thirties. Robust free cash conversion funds organic R&D while supporting enhanced shareholder distributions. |
| Q2 2030 | 327.43 | +1.07% | +57.34% | Competitive advances from alternative oral immunology agents introduce preliminary terminal growth caution. Established clinical switching barriers and deep patient retention limit prescription erosion, resulting in steady, low-beta trading. |
| Q3 2030 | 332.24 | +1.47% | +59.66% | Full commercial operationalization of domestic manufacturing infrastructure improves supply logistics and yields industrial efficiencies. Cash generation remains dependable, cushioning routine European statutory healthcare price cuts. |
| Q4 2030 | 337.96 | +1.72% | +62.40% | International commercial execution delivers predictable cash flow compounding, while low net leverage shields equity value from macroeconomic softness. Modest quarterly gains reflect steady owner earnings rather than multiple expansion. |
| Q1 2031 | 347.66 | +2.87% | +67.06% | Full-year disclosures confirm delivery of multi-year blockbuster revenue targets. Substantial balance sheet equity accumulation and record free cash flow prompt another dividend expansion, driving solid institutional demand. |
| Q2 2031 | 352.07 | +1.27% | +69.18% | Top-line revenue growth moderates to single digits as primary immunology indications approach mature market penetration. Steady prescription renewals and disciplined operational expenditures preserve healthy return on invested capital. |
| Q3 2031 | 358.02 | +1.69% | +72.04% | Terminal horizon cash flows reflect a fully transitioned biopharma leader with diversified orphan neurology and immunology cash streams. Unencumbered free cash yield supports durable structural valuation floors. |
UCB's investment case is defined by an accelerating product replacement cycle wherein flagship dual-cytokine biologic adoption outpaces legacy small-molecule and anti-TNF exclusivity expirations. As multi-indication scaling in hidradenitis suppurativa and psoriatic arthritis absorbs fixed manufacturing and distribution infrastructure, underlying operating leverageoperating leverageThe sensitivity of operating profit to changes in revenue caused by the mix of fixed and variable costs.View full glossary entry expands. However, investors must distinguish accounting optics from cash conversion: naive trailing price-to-earnings multiples of eleven times reflect semi-annual reporting distortions, whereas true normalized trailing multiples sit near eighteen times. Valuation sensitivity is governed by US gross-to-net rebate concessions and near-term capital absorption from manufacturing buildouts and biotechnology acquisitions.
Key insights
- Indication stacking across chronic dermatology and rheumatology indications generates high-margin volume growth that decisively neutralizes Briviact and mature Cimzia baseline attrition.
- Intermediate free cash flow conversionfree cash flow conversionThe proportion of earnings, EBITDA, or another operating measure converted into free cash flow over a specified period.View full glossary entry temporarily lags adjusted accounting EBITDAearnings before interest taxes depreciation and amortizationEarnings before interest, taxes, depreciation, and amortization (EBITDA) measures operating performance before financing, tax, and certain accounting charges.View full glossary entry due to working capitalworking capitalShort-term operating capital measured as current assets minus current liabilities.View full glossary entry expansion, Georgia biologics construction, and acquisition milestone commitments.
- Long-dated exclusivity running past 2033 on primary growth drivers provides an exceptional cash duration moat relative to large-cap European pharmaceutical peers.
UCB is successfully replacing its older, expiring medications with a powerful new generation of specialty biologic therapies. While older epilepsy and immunology treatments face generic competition, new treatments for severe skin and joint diseases are growing rapidly and taking market share. The business is becoming much more profitable because the heavy costs of developing these treatments are already paid, allowing new sales to generate strong underlying cash flow.
Key insights
- Rapid prescription growth in severe skin and autoimmune diseases is easily replacing sales lost to generic competitors.
- Cash flow is temporarily absorbed by new factory construction and research acquisitions, but long-term earnings are expanding.
- Core patented medicines enjoy legal exclusivity well into the 2030s, protecting profits from near-term generic copies.
Deep Dive
The market consensus treats UCB as an aging European specialty drugmaker whose recent share price pullback reflects peak margin exhaustion and patent vulnerability. Investors focus heavily on the 2026 loss of exclusivityloss of exclusivityRefers to the expiration of patent protection leading to generic or biosimilar competition for key drugs.View full glossary entry for antiepileptic Briviact, widening US pharmacy benefit manager rebate discounts, and heavy acquisition cash outflows, discounting raised multi-billion peak sales guidance as promotional optimism.
Paywalled preview begins: Deep Dive: detailed analysis
From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.
Deep Dive
Alpha Gap & Repricing Catalysts
Where does the current market narrative diverge from our AI Opinions—and what could close the gap?
Market Narrative
What does the market currently expect? The market consensus treats UCB as an aging European specialty drugmaker whose recent share price pullback reflects peak margin exhaustion and patent vulnerability. Investors focus heavily on the 2026 loss of exclusivityloss of exclusivityRefers to the expiration of patent protection leading to generic or biosimilar competition for key drugs.View full glossary entry for antiepileptic Briviact, widening US pharmacy benefit manager rebate discounts, and heavy acquisition cash outflows, discounting raised multi-billion peak sales guidance as promotional optimism.
Alpha Gap
What is the biggest difference between market expectations and our AI forecasts? The crowd underestimates value due to an analytical blind spot regarding the speed of UCB's product replacement cycle. Market participants confuse temporary working capitalworking capitalShort-term operating capital measured as current assets minus current liabilities.View full glossary entry absorption and front-loaded launch spending with permanent margin decay, while misinterpreting semi-annual accounting data as extreme low-multiple distress. In reality, the dual-inhibition immunology franchise is generating superior clinical switching that dwarfs legacy erosion, supported by durable exclusivities extending past 2033.
Repricing Catalyst
What could make the market recognize and close that gap? Consecutive audited financial releases demonstrating that underlying adjusted EBITDAadjusted ebitdaEBITDA modified to exclude selected items that management considers non-recurring or not representative of ongoing operations.View full glossary entry margins remain above thirty-four percent despite Briviact patent loss will trigger repricing. Confirmation that annualized flagship immunology sales exceed three point five billion euros while operating cash conversion rebounds will dismantle margin collapse theories, forcing sell-side analysts to lift forward earningsforward earningsEstimated future profitability used to calculate valuation multiples for investment analysis.View full glossary entry projections across the 2027 to 2028 monitoring window.
Sentiment and Timing
What do sentiment, volatility, and the market-recognition cycle suggest about the thesis timing?
- Greed / Fear
- Fear
- Volatility
- Moderate
- Cycle position
- Stabilization
Sentiment exhibits consensus stabilization following a steep post-earnings pullback. Reports agree that fear over near-term margin digestion is overdone, but diverge on whether recovery requires broad macro rate cuts or simple confirmation of commercial script delivery.
Macro Regime Fit
Does the current market environment support the thesis? The prevailing macroeconomic regimemacroeconomic regimeThe prevailing set of economic conditions including interest rates and inflation that influence asset pricing.View full glossary entry of elevated benchmark interest rates and persistent inflation is a relative tailwind for operating fundamentals but a headwind for valuation multiples. Non-cyclical chronic disease demand and minimal financial leverage insulate cash generation from credit shocks, though five percent sovereign yields compress long-duration equity multiples, making fundamental cash delivery the sole driver of returns.
Advisor Disagreement
What do our AI Advisors disagree about most? The primary analytical disagreement concerns the true baseline valuation multiplevaluation multipleA ratio comparing market or enterprise value with a financial measure such as earnings, revenue, book value, or cash flow.View full glossary entry and the durability of intermediate operating marginsoperating marginsOperating profit as a percentage of revenue after operating expenses, before interest and taxes.View full glossary entry. While several reports model an apparent eleven-times price-to-earnings ratio, forensic cross-examination proves this reflects semi-annual reporting stacking, establishing true trailing earnings multiples closer to eighteen times. A second debate divides views on margin trajectories: optimistic models project adjusted EBITDAadjusted ebitdaEBITDA modified to exclude selected items that management considers non-recurring or not representative of ongoing operations.View full glossary entry margins permanently exceeding forty percent, whereas conservative frameworks emphasize that US gross-to-net deductions, manufacturing capexcapital expenditureCapital expenditure (CAPEX) is spending on long-lived assets or major improvements expected to support operations over multiple periods.View full glossary entry in Georgia, and acquisition outlays will absorb near-term cash. Audited full-year 2026 cash conversion data will resolve whether recent margin expansionmargin expansionAn increase in profit as a percentage of revenue.View full glossary entry is structural or partially flattered by one-off rebate adjustments.
Base-Case Forces
Event Risk ScoreLow21/100Near-certain positive forces
Top Drivers / Tailwinds
Near-certain forces that support the investment thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Driver / Tailwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Multi-indication blockbuster immunology volume expansion | Competitive Positioning | +36% | +50% | Dual IL-17A and IL-17F cytokine inhibition demonstrates clinical superiority over legacy biologics in psoriasis, psoriatic arthritis, and hidradenitis suppurativa. Unprecedented clearing rates drive rapid first-line switching globally. With long-dated patent protection, volume expansion generates robust recurring revenuerecurring revenueRevenue expected to repeat under subscriptions, contracts, renewals, or recurring customer usage.View full glossary entry, elevating baseline operating income through the five-year forecast horizon. |
| Operating leverageoperating leverageThe sensitivity of operating profit to changes in revenue caused by the mix of fixed and variable costs.View full glossary entry from fixed infrastructure | Operational Efficiency | +20% | +30% | Having front-loaded clinical development and global commercial launch infrastructure between 2022 and 2025, incremental sales incur negligible marginal distribution expense. Manufacturing scale efficiencies in biologics fermentation widen operating marginsoperating marginsOperating profit as a percentage of revenue after operating expenses, before interest and taxes.View full glossary entry toward thirty-eight percent, translating top-line growth directly into compounding owner earningsowner earningsAn estimate of cash available to owners after operating costs, taxes, and the capital spending needed to maintain competitive capacity.View full glossary entry and free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry. |
| Specialty neurology and bone-health royalties | Innovation And Product | +16% | +20% | Evenity profit-sharing royalties alongside specialty commercial scaling of rare neurology therapies generate high-margin diversified revenue. Non-cyclical orphan indications provide strong pricing powerpricing powerThe ability of a company to raise prices without losing significant customer demand.View full glossary entry and high patient retention, buffering aggregate cash flows against mass-market reimbursement pressures and single-molecule concentration risks. |
| Balance sheetbalance sheetA financial statement showing assets, liabilities, and equity at a specific point in time.View full glossary entry self-funding and deleveragingdeleveragingThe process of reducing total debt and leverage to strengthen financial stability.View full glossary entry | Capital Allocation | +11% | +12% | Surging operational cash flows comfortably absorb recent pipeline acquisition costs, driving net leverage down and maintaining interest coverage above nine times. Solvency resilience eliminates refinancing vulnerabilities in high-rate environments, allowing management to fund progressive dividend distributions and selective share buybacks without balance-sheet strain. |
Near-certain negative forces
Top Frictions / Headwinds
Near-certain forces that could slow, cap, or damage the thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Friction / Headwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Mature antiepileptic and legacy patent runoff | Competitive Positioning | -14% | -18% | The loss of exclusivityloss of exclusivityRefers to the expiration of patent protection leading to generic or biosimilar competition for key drugs.View full glossary entry for antiepileptic Briviact in 2026, alongside ongoing baseline volume erosion for mature anti-TNF biologic Cimzia, creates a significant top-line revenue drag. Generic and biosimilar substitution across major Western markets strips away hundreds of millions in high-margin revenue, partially offsetting new product gains. |
| US pharmacy benefit manager rebate widening | Regulatory | -12% | -15% | Securing preferred commercial and Medicare formulary access in the United States requires aggressive statutory discounts and gross-to-net concessions. Mandatory rebate expansion compresses realized net price per prescription, limiting top-line cash conversion and imposing persistent structural downward pressure on gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry despite explosive volume adoption. |
| Acquisition integration and clinical development drag | Capital Allocation | -9.0% | -10% | Absorbing multi-billion-dollar clinical acquisitions, including Candid Therapeutics and Neurona Therapeutics, commits substantial capital toward ongoing trials. Research spending approaching twenty-five percent of sales and contingent development milestones absorb near-term operating cash, muting intermediate free cash flow conversionfree cash flow conversionThe proportion of earnings, EBITDA, or another operating measure converted into free cash flow over a specified period.View full glossary entry during active pipeline integration. |
| Healthcare procurement austerity and tariffs | Political And Geopolitical | -8.0% | -7.0% | European sovereign fiscal strain enforces stringent cost-effectiveness hurdles and statutory price clawbacks on specialty therapies. Concurrently, unresolved transatlantic pharmaceutical tariff frameworks impose administrative and duty friction on European exports into the United States, trimming realized margins across key international trade corridors. |
What Could Break or Accelerate the Thesis
Plausible downside scenarios
Tail Risks
Tail yet plausible downside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Severe class-wide boxed safety warning | 20% | -30% | Post-marketing pharmacovigilance surveillance identifying unexpected systemic fungal infections or psychiatric adverse events could prompt regulatory agencies to mandate restrictive black-box warnings. Mandatory risk evaluation strategies would sharply decelerate new patient starts, curtailing peak sales expectations across primary dermatological indications. |
| Radical US drug price negotiation expansion | 25% | -22% | Sweeping legislative changes shortening statutory biologic exemption windows under United States Medicare price negotiation frameworks would impose premature mandatory discounts on key commercial drivers. Forcing fifty percent price reductions would decimate gross profit marginsgross profit marginsThe share of revenue left after subtracting cost of goods sold.View full glossary entry across the company's most lucrative commercial territory. |
Plausible upside scenarios
Tail Opportunities
Tail yet plausible upside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Clinical triumph in atopic dermatitis | 32% | +26% | Pivotal clinical trial validation for pipeline assets in moderate-to-severe atopic dermatitis by 2028 would breach an entrenched multi-billion-euro market. Proving superior cutaneous clearance would add substantial peak sales beyond current guidance, triggering aggressive upward revisions in consensus forward earningsforward earningsEstimated future profitability used to calculate valuation multiples for investment analysis.View full glossary entry. |
| Curative cell therapy epilepsy breakthrough | 25% | +22% | Acquired regenerative cell therapy rezanecel demonstrating sustained seizure freedom in drug-resistant mesial temporal lobe epilepsy would establish a revolutionary disease-modifying franchise. Curative validation would command premium orphan pricing and expand terminal enterprise valuation well beyond traditional small-molecule neurology multiples. |
Company Financial Analysis
UCB Earnings and Financials Analysis by AI
Financial figures available as of Sep 20, 2026. Only filings and source records available by this analysis date are included.
Earnings and financials
AI Review
UCB's financial performance demonstrates an operational turnaround as new growth therapies reach commercial scale. Full-year 2025 revenue grew 25.8% to 7.74 billion euros, while first-half 2026 revenue expanded another 22.5% to 4.27 billion euros. Strong prescription uptake for flagship immunology and rare disease products is comfortably overcoming generic erosion from older off-patent medicines. However, retail investors must understand that headline profits currently run ahead of actual cash collection. While first-half 2026 net income jumped to 1.11 billion euros, cash generation was tempered by rising customer receivables and inventory buildup. The business is fundamentally strengthening, but reported earnings reflect accounting gains before cash is fully realized.
Revenue, earnings, and cash flow
The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.
| Fiscal year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | EUR 7.7B | EUR 1.6B | EUR 1.9B |
| 2024 | EUR 6.2B | EUR 1.1B | EUR 920M |
| 2023 | EUR 5.3B | EUR 343M | EUR 445M |
| 2022 | EUR 5.5B | EUR 418M | EUR 748M |
| 2021 | EUR 5.8B | EUR 1.1B | EUR 1.1B |
Valuation context: historical P/E
The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.
| Fiscal year | P/E | Earnings basis | Currency basis | Ticker / reporting |
|---|---|---|---|---|
| 2025 | 17.3x | TTM | Native | EUR / EUR |
| 2024 | 26.5x | TTM | Native | EUR / EUR |
| 2023 | -- | TTM | Unavailable | EUR / EUR |
| 2022 | 33.8x | Annual | Native | EUR / EUR |
| 2021 | 18.4x | Annual | Native | EUR / EUR |
P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.
Profitability and margins
AI Review
Profit margins are undergoing a structural expansion as expensive, patent-protected biologics displace older chemical drugs. Gross margin held firmly above 71% in 2025 and widened toward 82% in first-half 2026, driven by high manufacturing efficiency and the rapid growth of high-margin specialty treatments. Adjusted operating margins reached an impressive 40.7% in early 2026, though management caution suggests this was temporarily boosted by favorable rebate accounting. As UCB broadens patient access in the United States, mandatory insurance discounts will moderate future realized prices. Overall profitability will comfortably exceed historical company averages as fixed commercial expenses spread over expanding sales.
The table compares up to five fiscal years of operating income and reported profitability margins.
| Fiscal year | Operating income | Operating margin | Net margin |
|---|---|---|---|
| 2025 | EUR 1.2B | 15.1% | 20.1% |
| 2024 | EUR 1.3B | 21.5% | 17.3% |
| 2023 | EUR 604M | 11.5% | 6.5% |
| 2022 | EUR 400M | 7.3% | 7.6% |
| 2021 | EUR 1.1B | 19.9% | 18.3% |
Balance sheet and leverage
AI Review
UCB maintains a solid balance sheet backed by 10.87 billion euros in shareholder equity. Debt-to-equity stood at a conservative 0.21 at year-end 2025, with an interest coverage ratio exceeding nine times. This conservative structure confirms the company carries virtually no near-term solvency or debt refinancing risk under high interest rates. Nevertheless, headline net debt increased in mid-2026 following substantial cash outlays for biotechnology acquisitions. While current debt remains manageable at roughly 0.8 times annual operating cash flow, upcoming clinical trial commitments and factory construction leave limited room for unfinanced mega-deals. Strong recurring prescription cash flows ensure organic debt reduction without diluting shareholders.
The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.
| Fiscal year | Total debt | Cash + short-term investments | Net cash / (debt) | Current ratio |
|---|---|---|---|---|
| 2025 | EUR 2.2B | EUR 2.5B | EUR 6M net cash | 1.38x |
| 2024 | EUR 3B | EUR 1.8B | EUR 1.5B net debt | 1.36x |
| 2023 | EUR 3B | EUR 969M | EUR 2.2B net debt | 1.32x |
| 2022 | EUR 2.9B | EUR 1.1B | EUR 2B net debt | 1.06x |
| 2021 | EUR 2.1B | EUR 1.4B | EUR 860M net debt | 1.31x |
Net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.
Capex and investment intensity
AI Review
Management has shifted capital allocation from routine physical factory construction toward strategic scientific investments. Physical property spending absorbed a modest 3.6% of revenue in 2025, but total cash deployment surged in 2026 through the acquisitions of Candid Therapeutics and Neurona Therapeutics, committing over 2.6 billion dollars to secure next-generation medicines. Additionally, UCB has committed long-term capital to construct a dedicated biologic manufacturing facility in Georgia. This major project secures domestic production for the American market, protecting supply chains against potential tariffs. While these strategic outlays absorb cash today, they establish crucial product ownership that protects earnings well into the 2030s.
The table compares up to five fiscal years of capital expenditure and research-and-development investment.
| Fiscal year | Capital expenditure | R&D spend |
|---|---|---|
| 2025 | EUR 281M | EUR 1.8B |
| 2024 | EUR 322M | EUR 1.8B |
| 2023 | EUR 316M | EUR 1.6B |
| 2022 | EUR 371M | EUR 1.7B |
| 2021 | EUR 493M | EUR 1.6B |
Quarterly Forecast Scenarios
UCB Averaged Consensus Scenarios
One row per forecast quarter. Asset scenario targets are shown in EUR; benchmark values are shown in USD.
Scroll to view all columns
| Quarter | Bear case (EUR) | Base case (EUR) | Bull case (EUR) | S&P 500 benchmark (USD) | FX (EUR/USD) |
|---|---|---|---|---|---|
| €212.26 | €216.28 | €220.59 | $750.26 | 1.1360 | |
| €220.75 | €228.96 | €238.23 | $736.44 | 1.1255 | |
| €214.13 | €236.21 | €250.14 | $743.40 | 1.1272 | |
| €224.84 | €244.47 | €260.15 | $755.15 | 1.1312 | |
| €233.83 | €251.27 | €267.95 | $776.22 | 1.1401 | |
| €245.52 | €264.04 | €281.35 | $787.13 | 1.1452 | |
| €248.51 | €271.06 | €289.90 | $802.83 | 1.1510 | |
| €240.41 | €278.35 | €298.59 | $812.05 | 1.1584 | |
| €252.44 | €285.83 | €310.54 | $839.18 | 1.1617 | |
| €265.06 | €297.72 | €326.06 | $850.50 | 1.1694 | |
| €267.71 | €301.84 | €332.59 | $872.39 | 1.1719 | |
| €275.74 | €308.69 | €342.56 | $885.51 | 1.1763 | |
| €282.58 | €314.41 | €349.42 | $909.56 | 1.1781 | |
| €288.23 | €325.01 | €363.39 | $916.13 | 1.1832 | |
| €289.29 | €329.07 | €370.66 | $936.51 | 1.1867 | |
| €296.93 | €333.95 | €374.37 | $947.34 | 1.1894 | |
| €299.90 | €339.17 | €381.85 | $969.59 | 1.1887 | |
| €305.90 | €348.39 | €393.31 | $979.99 | 1.1913 | |
| €305.90 | €352.38 | €397.24 | $999.60 | 1.1971 | |
| €308.96 | €358.14 | €405.19 | $1,012 | 1.1964 |
Behind the synthesis
How each opinion shapes the consensus
The common causal pattern across all submissions is that accelerating volume adoption of newly launched biologics overwhelms generic runoff from legacy antiepileptics and mature anti-TNF therapies. However, reports diverge sharply on valuation and cash conversion. Several submissions uncritically cite an apparent trailing price-to-earnings multiple of eleven times, failing to recognize this as an artifact of stacking four half-year periods for a semi-annual reporter. Forensic scrutiny reveals the normalized trailing multiple sits near eighteen times. Furthermore, while headline accounting margins expanded toward forty percent in early 2026, working capital absorption, manufacturing capex in Georgia, and acquisition outlays across Candid and Neurona consume significant intermediate cash. Consequently, higher weights are awarded to reports that correctly reconcile semi-annual financials, model gross-to-net rebate concessions, and incorporate tariff risks. Purely narrative reports accepting unadjusted multiples or extrapolating margin peaks without accounting for structural payer friction receive reduced weights.
Universal Investor AI
The Polymath
GPT-6 AstraFeatures superior accounting rigor, correctly identifying that naive trailing price-to-earnings metrics reflect semi-annual reporting artifacts rather than extreme undervaluation. It models working capital drains, Georgia capex commitments, and gross-to-net concessions with unmatched precision.
Universal Investor AI
The Polymath
Opus 5Exceptional critical analysis identifying the reconstructed eighteen-times trailing earnings baseline and quantifying US tariff and policy frictions. It provides nuanced treatment of capital commitments across Candid and Neurona, delivering a realistic, evidence-backed valuation path.
Michael Burry AI
The Vulture
Gemini 3.8 FlashDelivers an incisive forensic dissection of the replacement cycle, correctly distinguishing Briviact patent runoff from expanding biologic volume. It demonstrates strong source verification, grounded margin assumptions, and realistic treatment of acquisition-related debt and liquidity.
J.P. Morgan AI
The Titan
Gemini 3.8 FlashOffers rigorous evidence on multi-indication expansion across hidradenitis suppurativa and psoriatic arthritis, backed by solid primary sources. However, its margin trajectory leans overly optimistic by discounting gross-to-net rebate compression and acquisition absorption costs.
Universal Investor AI
The Polymath
Gemini 3.8 FlashAccurately details commercial scaling and working capital absorption from recent bolt-on transactions. The path is economically consistent, though slightly aggressive in assuming sustained forty percent margins against intensifying European healthcare procurement austerity.
Ray Dalio AI
The Strategist
Gemini 3.8 FlashPresents strong causal reasoning connecting manufacturing investments in Georgia with long-term supply autonomy. The analysis appropriately balances Briviact patent expiry against immunology growth, though its interest rate sensitivity assumption appears somewhat overstated.
Warren Buffett AI
The Value Seeker
Gemini 3.8 FlashProvides a high-quality assessment of owner earnings, competitive moats, and balance sheet deleveraging. It sensibly models the dual-inhibition mechanism's clinical superiority while slightly downplaying the friction of US pharmacy benefit manager rebate structures.
Niccolo Machiavelli AI
The Insider
Gemini 3.8 FlashAnalyzes the governance moat provided by the Tubize anchor shareholder and Belgian intellectual property tax regimes. While identifying genuine structural protections, it underweights prospective payer price renegotiation mechanisms across mature European markets.
Universal Investor AI
The Polymath
Gemini 3.8 FlashThe report presents sound fundamental analysis of Bimzelx commercial adoption and operating leverage, but accepts trailing valuation metrics without adjusting for semi-annual reporting distortions. It captures core volume dynamics well while underestimating near-term acquisition integration drag.
Superintelligence AI
The Anthropologist
Gemini 3.8 FlashOutlines the generational portfolio pivot into immunology and rare disease niches, but relies on flawed trailing valuation multiples. Its long-term operating leverage narrative is compelling, though terminal margin projections appear somewhat unconstrained.
Warren Buffett AI
The Value Seeker
Gemini 3.8 FlashEffectively highlights the durability of Evenity royalties and rare disease cash flows. However, it repeats unadjusted trailing multiple figures and understates the near-term working capital required to support rapid international commercial expansion.
Superintelligence AI
The Anthropologist
Gemini 3.8 FlashArticulates the tension between temporary post-launch cost absorption and underlying volume momentum. The qualitative evaluation of clinical trial moats is strong, but the numerical trajectory underestimates ongoing US gross-to-net discount widening.
Elon Musk AI
The Visionary
Gemini 3.8 FlashPresents a vivid technological critique of biologic competition, but overstates potential disruption from early-stage nanobodies while repeating uncorrected trailing earnings multiples. The near-term return trajectory is somewhat aggressively front-loaded.
Sherlock Holmes AI
The Whistleblower
Gemini 3.8 FlashOffers helpful forensic detail on Evenity profit recognition and pegylated manufacturing barriers for Cimzia. However, its valuation conclusions partially rely on unadjusted headline multiples, slightly blunting its overall analytical precision.
Research Provenance
References & Context
This UCB consensus analysis combines structured market evidence with independent AI-agent forecasts. External references below are limited to sources recorded by the researcher agents for this forecast batch.
Primary analysis inputs
- iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
- iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
- Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
- Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
- Researcher web evidence — public sources consulted to challenge and contextualize the forecast thesis.
Independent AI Advisor panel
- AI Advisors
- 14
- AI Researchers
- 11
- AI Thinkers
- 3
Sources retained from AI Researcher searches
Asset-specific · Researcher webShowing the top 15 of 84 deduplicated sources retained for this batch.
- 01CMS Announces Manufacturer Participation in Third Cycle of Medicare Drug Price Negotiation | CMScms.gov
- 02Drug Trials Snapshots: ICOTYDE | FDAfda.gov
- 03UCB stock edges lower as investors weigh Cimzia review and valuation gapad-hoc-news.de
- 04UCB stock gains as Baader Europe lifts price target on valuation opportunityad-hoc-news.de
- 05UCB stock steadies as investors await next updatead-hoc-news.de
- 06UCB.BR Stock Price, Quote & Chart | ChartMill.comchartmill.com
- 07U.S. Pharma Tariffs And MFN Become Law After April 2 Updateclinicalleader.com
- 08A New Round in US Pharma Tariffs: What's at Play? - DCAT Value Chain Insightsdcatvci.org
- 09UCB strikes $1.15B deal for cell therapy biotech Neuronafiercebiotech.com
- 10UCB's fast-growing Bimzelx leaps across blockbuster sales threshold as HS momentum buildsfiercepharma.com
- 11UCBJY H1 FY2026 earnings call — BigGo Financefinance.biggo.com
- 12UCB acquires Candid Therapeutics in $2.22bn deal — Financier Worldwidefinancierworldwide.com
- 13Half Year 2026 Ucb SA Earnings Call Transcriptgurufocus.com
- 14Earnings call transcript: UCB lifts 2026 outlook as BIMZELX sales double in H1 2026 By Investing.cominvesting.com
- 15UCB SA FY25 EBITDA jumps on Bimzelx surge; margin hit by one-offs By Investing.cominvesting.com
And 69 more sources were used and retained in the batch inventory.
Context retained with this Consensus
The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.
Global context snapshot
2025 Full-Year Global Market and World-Events Context
Download Archived SnapshotCoverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31
This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.
The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| DeepSeek shock and AI economics reset | 2025-01-27 | OPEN ENDED TREND |
| US tariff regime escalation and trade-system rupture | 2025-02-01 | ACTIVE POLICY REGIME |
| Federal Reserve easing cycle after a prolonged hold | 2025-09-17 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
2026 Year-to-Date Global Market and World-Events Context Through September 20
Download Archived SnapshotCoverage 2026-01-01 to 2026-09-20 · Knowledge cutoff 2026-09-20
January 1-September 20, 2026: monetary tightening, energy security, trade restrictions, AI financing and divergent growth; five leading market themes.
Fed raised rates to 3.75%-4.00%; ECB hike is in force and BOJ increase starts September 24. Markets through September 18, bitcoin through September 19.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| Renewed monetary tightening amid persistent inflation | 2026-01-30 | ACTIVE POLICY REGIME |
| Iran/Hormuz conflict and wider energy-security disruption | 2026-02-28 | ONGOING |
| Tariff legal reset and strategic supply restrictions | 2026-02-20 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
Fundamental context
Income statement
9 fieldsdepreciationAndAmortization · ebit · ebitda · grossProfit · +5 more fields
Balance sheet
12 fieldscash · commonStockSharesOutstanding · longTermDebt · netDebt · +8 more fields
Cash flow
5 fieldscapitalExpenditures · dividendsPaid · freeCashFlow · salePurchaseOfStock · +1 more field
annual: 2014-12-31–2025-12-31, 12 periods; quarterly: 2023-12-31–2026-06-30, 6 periods
Currencies cited: EUR, USD (quote EUR; primary reporting EUR; converted/valuation USD).
End of the paywalled preview
The excerpt from Deep Dive: detailed analysis to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.
Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.
Additional with full access
Individual AI Advisor reports
- Investment theses
- Bull and bear scenarios and alpha signals
- Drivers, headwinds, risks and opportunities
- Quarterly forecast rationale
- Advisor research references and configuration
Additional datasets and interactive tools
- Interactive forecast comparisons
- Available detailed financial statements
- Market history and corporate-action adjustments
- Eligible historical publication workspaces
Explore complete public research examples
These public assets show the complete AI Consensus research. Their findings concern those assets, not this report.